Back to Oncology
Oncologyv2021Evidence-Based

Immune-Related Adverse Events for Endocrine Toxicities - Hypothyroidism

Grades severity of hypothyroidism secondary to immune checkpoint inhibitor therapy and provides management recommendations

Clinical Input Parameters

mIU/L
Range: 0.01 — 100 mIU/L
Clinical Assessment
Awaiting Parameters
irae grade
—grade
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The Immune-Related Adverse Events for Endocrine Toxicities - Hypothyroidism is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within oncology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

Grading based on TSH levels (mIU/L), symptom severity, and presence of myxedema: Grade 1 (TSH <10, asymptomatic), Grade 2 (TSH >10 OR moderate symptoms with ADL preservation), Grade 3 (severe symptoms, unable to perform ADLs), Grade 4 (myxedema coma or life-threatening complications)

Clinical Pearls & Practice Notes

  • Based on Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0
  • More common with anti-PD-1/PD-L1 agents than anti-CTLA-4
  • Can occur at any time during ICPi treatment, often irreversible
  • TSH elevation may precede clinical symptoms by weeks to months
  • Normal TSH range typically 0.4-4.0 mIU/L, varies by laboratory
  • Grade 2+ requires endocrinology consultation for hormone replacement
  • Most patients require lifelong thyroid hormone replacement
  • Monitor for concurrent adrenal insufficiency (up to 50% association)
  • Free T4 levels help distinguish primary from secondary hypothyroidism
  • Subclinical hypothyroidism (elevated TSH, normal T4) may not require treatment
  • ICPi therapy can often be resumed after hormone replacement initiated
  • Consider thyroid peroxidase (TPO) and thyroglobulin antibodies
  • Myxedema coma mortality rate 20-60% despite treatment
  • Distinguish from pre-existing thyroid disease or medication effects

Evidence & Literature Citations

  1. Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018 Jun 10;36(17):1714-1768. doi: 10.1200/JCO.2017.77.6385.
  2. Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, et al. NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. J Natl Compr Canc Netw. 2020 Mar 1;18(3):230-241. doi: 10.6004/jnccn.2020.0012.
  3. Faje AT, Sullivan R, Lawrence D, Trombetta M, Fadden R, Klibanski A, et al. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab. 2014 Nov;99(11):4078-85. doi: 10.1210/jc.2014-2306.
  4. Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min Y, Krop IE, et al. Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis. JAMA Oncol. 2018 Feb 1;4(2):173-182. doi: 10.1001/jamaoncol.2017.3064.

Score Interpretation Ranges

Tier 11 – 1 pts

Mild - Asymptomatic with TSH <10 mIU/L

Tier 22 – 2 pts

Moderate - Moderate symptoms, able to perform ADLs, TSH >10 mIU/L

Tier 33 – 3 pts

Severe - Severe symptoms, unable to perform ADLs

Tier 44 – 4 pts

Life-threatening - Myxedema coma or life-threatening consequences

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.